Bio-Rad Laboratories Inc
Company Profile
Business description
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Contact
1000 Alfred Nobel Drive
HerculesCA94547
USAT: +1 510 724-7000
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2026
Employees
7,700
Stocks News & Analysis
stocks
Navigating the ASX dividend landscape in 2026
stocks
Meta stock has struggled amid AI spending concerns. Is it a buy?
stocks
Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,108.60 | 16.20 | 0.18% |
| CAC 40 | 8,079.50 | 16.92 | 0.21% |
| DAX 40 | 24,610.95 | 92.17 | -0.37% |
| Dow JONES (US) | 48,940.34 | 451.75 | 0.93% |
| FTSE 100 | 10,150.52 | 23.74 | 0.23% |
| HKSE | 26,585.06 | 97.55 | 0.37% |
| NASDAQ | 23,158.12 | 203.80 | 0.89% |
| Nikkei 225 | 52,774.64 | 216.46 | -0.41% |
| NZX 50 Index | 13,417.17 | 156.76 | -1.15% |
| S&P 500 | 6,857.11 | 60.25 | 0.89% |
| S&P/ASX 200 | 8,782.90 | 14.00 | 0.16% |
| SSE Composite Index | 4,116.94 | 3.29 | 0.08% |